Anlotinib Anticancer Drugs Oncology Pharmacology Physiotherapy

Anlotinib (Background-3)

In this article we will discuss Anlotinib (Background-3)

To date, targeted RTK inhibitors have been successfully utilized in the treatment of several cancer types. Most of these inhibitors are multi-targeting drugs such as imatinib, sorafenib, sunitinib, and pazopanib, which achieve therapeutic efficacy in some tumors. For example, sorafenib inhibits multiple targets including the vascular endothelial growth factor (VEGF) receptors, VEGFR-1, VEGFR-2, and VEGFR-3, as well as Raf serine/threonine kinases and platelet-derived growth factor receptor (PDGFR)-β

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.